Soleno Therapeutics Inc [SLNO] stock is trading at $56.29, up 1.77%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SLNO shares have gain 4.94% over the last week, with a monthly amount glided 11.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on September 03, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $70. Previously, Robert W. Baird started tracking the stock with Outperform rating on May 10, 2024, and set its price target to $72. On February 05, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $93 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $63 on January 23, 2024. Guggenheim started tracking with a Buy rating for this stock on September 29, 2020, and assigned it a price target of $8. In a note dated January 10, 2020, Craig Hallum initiated an Buy rating and provided a target price of $8 on this stock.
Soleno Therapeutics Inc [SLNO] stock has fluctuated between $21.30 and $57.28 over the past year. Currently, Wall Street analysts expect the stock to reach $76 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $56.29 at the most recent close of the market. An investor can expect a potential return of 35.02% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -19.83%, Pretax Profit Margin comes in at -18.98%, and Net Profit Margin reading is -18.98%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.43 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.31 points at the first support level, and at 54.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.89, and for the 2nd resistance point, it is at 57.49.
Ratios To Look Out For
For context, Soleno Therapeutics Inc’s Current Ratio is 29.24. Further, the Quick Ratio stands at 29.24, while the Cash Ratio is 6.23.
Transactions by insiders
Recent insider trading involved Abingworth Bioventures VII LP, Rule 144 Affiliate, that happened on Oct 21 ’24 when 0.95 million shares were purchased. Rule 144 Affiliate, Abingworth Bioventures VII LP completed a deal on Oct 07 ’24 to buy 2.52 million shares. Meanwhile, Yen Kristen sold 3108.0 shares on Oct 01 ’24.
